Multiple Sclerosis and Erectile Dysfunction: The MS-ED Connection Explained

Yes — sexual dysfunction is common in MS: in a case-control study it was present in 73.1% of patients with MS (men reported it more often than women) versus 12.7% of healthy controls [1]. Primary cause: demyelination of spinal cord pathways controlling erection. Secondary causes: fatigue, spasticity, bladder problems, and depression — all independently impair sexual function. Zorzon et al. found 63.2% of men with MS reported impotence or erectile dysfunction. MS-associated ED requires neurological-aware assessment and management.

Yes — PDE5 inhibitors (sildenafil, tadalafil) are effective first-line treatment for MS-associated ED. Sildenafil has been studied in small MS-specific RCTs with positive results. Daily low-dose tadalafil is often preferred for men with MS because it also improves overactive bladder symptoms — addressing two common MS symptoms simultaneously. Men with MS should start at lower doses due to potential hypotensive effects.

MS affects male sexual function at three levels: (1) primary — demyelination directly disrupts spinal cord erection pathways; (2) secondary — MS symptoms (fatigue, spasticity, pain, bladder urgency) physically impair sexual activity; (3) tertiary — psychological impact (depression, anxiety, relationship changes) reduces desire and causes performance anxiety. All three levels require separate management strategies for optimal sexual rehabilitation.

Generally yes — men with more advanced disease, greater overall disability, and lesions affecting the spinal cord specifically tend to have higher rates and greater severity of sexual dysfunction, though ED can occur even in men with relatively mild or early-stage MS due to lesion location mattering as much as overall disease burden. A single well-placed spinal cord lesion can meaningfully affect sexual function even in a man whose MS is otherwise mild by standard disability measures, which is why individual assessment matters more than assuming disease severity alone predicts sexual function.

Sometimes, particularly for the secondary and tertiary contributors — well-controlled MS with less fatigue, less spasticity, and better mood tends to support better sexual function through those pathways. Primary neurological damage from past demyelinating lesions, however, doesn't necessarily reverse even with excellent current disease control, since existing structural nerve damage is generally not reversible even when active disease progression is halted. This is why even well-controlled MS can still involve persistent ED requiring direct treatment.

Interferon beta specifically has documented associations with reduced testosterone in some studies, which can contribute to sexual dysfunction independent of the disease itself. Other disease-modifying therapies vary in their sexual side-effect profiles, and this is a reasonable topic to discuss with a neurologist when reviewing treatment options, particularly if ED developed or worsened around the same time a specific medication was started or changed. Switching disease-modifying therapy solely for sexual side effects is a significant decision that has to weigh the medication's effectiveness for the underlying MS, not something adjusted lightly.

It can help specifically with the secondary contributors — spasticity affecting positioning, and in some cases bladder-related symptoms that create anxiety around sexual activity — even though it doesn't address the primary neurological demyelination itself. A physical therapist experienced with neurological conditions can teach positioning strategies and pelvic floor relaxation techniques that reduce spasticity-related interference during sexual activity, making it a reasonable complementary approach alongside medical ED treatment rather than a standalone solution.

Men diagnosed at a younger age often face sexual dysfunction as a new, unexpected disruption to an established sexual identity and relationship pattern, which can carry a distinct emotional weight compared to men diagnosed later in life who may already be navigating some degree of age-related sexual change independently of MS. Neither experience is inherently easier, but the specific psychological context — a younger man grappling with an unexpected chronic diagnosis versus an older man distinguishing MS-related change from ordinary aging — can shape how sexual dysfunction is processed and what kind of support feels most relevant.

Yes — major MS advocacy and research organizations frequently maintain dedicated resources and sometimes specialized clinics addressing sexual health specifically within the broader context of MS care, recognizing this as a common but historically underdiscussed aspect of the disease. Bringing up interest in these resources with a neurologist or MS care team, rather than assuming sexual health falls entirely outside the scope of MS-specific care, can connect a man to more specialized support than a general urology visit alone might provide.

Yes — sexual dysfunction is common in women with MS as well, through overlapping mechanisms (demyelination affecting relevant neural pathways, fatigue, spasticity, and psychological impact), though the specific symptoms differ given anatomical and physiological differences. This is worth knowing for couples where both partners may be navigating MS-related changes to their relationship, or where a partner's own understanding of MS's broad-reaching effects can inform mutual support and shared problem-solving around intimacy.